Havens Advisors LLC cut its stake in shares of Humana Inc. (NYSE:HUM) by 64.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,000 shares of the insurance provider’s stock after selling 19,984 shares during the period. Humana makes up approximately 1.5% of Havens Advisors LLC’s holdings, making the stock its 18th largest position. Havens Advisors LLC’s holdings in Humana were worth $1,946,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently made changes to their positions in the stock. Capstone Asset Management Co. increased its stake in Humana by 0.9% in the third quarter. Capstone Asset Management Co. now owns 13,373 shares of the insurance provider’s stock worth $2,366,000 after buying an additional 124 shares during the period. Creative Planning increased its stake in Humana by 9.4% in the third quarter. Creative Planning now owns 7,174 shares of the insurance provider’s stock worth $1,269,000 after buying an additional 619 shares during the period. Daiwa SB Investments Ltd. increased its stake in Humana by 1.4% in the third quarter. Daiwa SB Investments Ltd. now owns 730 shares of the insurance provider’s stock worth $129,000 after buying an additional 10 shares during the period. Fulton Bank N.A. bought a new stake in Humana during the third quarter worth about $229,000. Finally, BNP Paribas Arbitrage SA increased its stake in Humana by 86.3% in the third quarter. BNP Paribas Arbitrage SA now owns 20,317 shares of the insurance provider’s stock worth $3,594,000 after buying an additional 9,414 shares during the period. Institutional investors own 91.71% of the company’s stock.

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Shares of Humana Inc. (NYSE:HUM) traded up 0.06% during midday trading on Monday, reaching $208.00. 1,871,598 shares of the company’s stock traded hands. The firm has a market capitalization of $31.01 billion, a PE ratio of 28.13 and a beta of 0.80. The stock’s 50-day moving average price is $182.87 and its 200 day moving average price is $177.74. Humana Inc. has a one year low of $150.00 and a one year high of $210.30.

Humana (NYSE:HUM) last posted its earnings results on Friday, November 4th. The insurance provider reported $3.18 earnings per share for the quarter, topping the consensus estimate of $3.09 by $0.09. The firm earned $13.69 billion during the quarter, compared to the consensus estimate of $13.41 billion. Humana had a net margin of 2.00% and a return on equity of 12.32%. The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter last year, the company earned $2.16 earnings per share. On average, equities research analysts expect that Humana Inc. will post $9.51 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 27th. Stockholders of record on Thursday, January 12th will be paid a $0.29 dividend. The ex-dividend date of this dividend is Tuesday, January 10th. This represents a $1.16 annualized dividend and a dividend yield of 0.56%. Humana’s payout ratio is 15.96%.

TRADEMARK VIOLATION NOTICE: “Havens Advisors LLC Has $1,946,000 Position in Humana Inc. (HUM)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/28/havens-advisors-llc-has-1946000-position-in-humana-inc-hum.html.

A number of analysts recently issued reports on the stock. Argus restated a “hold” rating on shares of Humana in a report on Tuesday, August 23rd. Cantor Fitzgerald restated a “buy” rating on shares of Humana in a report on Monday, August 8th. Zacks Investment Research downgraded shares of Humana from a “buy” rating to a “hold” rating in a report on Wednesday, September 21st. Evercore ISI assumed coverage on shares of Humana in a report on Thursday, September 22nd. They set a “buy” rating and a $200.00 price objective for the company. Finally, Barclays PLC decreased their price objective on shares of Humana from $193.00 to $191.00 and set an “equal weight” rating for the company in a report on Thursday, August 4th. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Humana currently has an average rating of “Buy” and an average price target of $205.00.

Humana Company Profile

Humana Inc is a health and well-being company. The Company’s segments include Retail, Group, Healthcare Services and Other Businesses. The Retail segment consists of Medicare benefits, marketed to individuals or directly via group accounts, as well as individual commercial fully-insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.

5 Day Chart for NYSE:HUM

Receive News & Stock Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related stocks with our FREE daily email newsletter.